Immunovant Net Income
| IMVT Stock | USD 26.68 0.40 1.52% |
As of the 18th of February 2026, Immunovant retains the Market Risk Adjusted Performance of 0.1942, downside deviation of 2.54, and Risk Adjusted Performance of 0.0745. Immunovant technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Analyzing historical trends in various income statement and balance sheet accounts from Immunovant's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Immunovant's valuation are summarized below:There are currently one hundred twenty fundamental trends for Immunovant that can be evaluated and compared over time across competitors. All traders should confirm Immunovant's regular fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Enterprise Value is likely to gain to about 1.4 B in 2026, whereas Market Cap is likely to drop slightly above 918.7 M in 2026. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -372.5 M | -353.8 M | |
| Net Loss | (405.00) | (425.25) | |
| Net Loss | (450.00) | (472.50) | |
| Net Loss | (2.46) | (2.58) | |
| Net Income Per E B T | 0.90 | 0.80 |
Immunovant | Net Income | Build AI portfolio with Immunovant Stock |
The evolution of Net Income for Immunovant provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Immunovant compares to historical norms and industry peers.
Latest Immunovant's Net Income Growth Pattern
Below is the plot of the Net Income of Immunovant over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Immunovant financial statement analysis. It represents the amount of money remaining after all of Immunovant operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Immunovant's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunovant's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (413.84 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Immunovant Net Income Regression Statistics
| Arithmetic Mean | (135,800,375) | |
| Coefficient Of Variation | (73.55) | |
| Mean Deviation | 59,433,118 | |
| Median | (136,740,000) | |
| Standard Deviation | 99,877,712 | |
| Sample Variance | 9975.6T | |
| Range | 413.8M | |
| R-Value | (0.06) | |
| Mean Square Error | 10607.2T | |
| R-Squared | 0 | |
| Significance | 0.83 | |
| Slope | (1,108,742) | |
| Total Sum of Squares | 159608.9T |
Immunovant Net Income History
Other Fundumenentals of Immunovant
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Immunovant Net Income component correlations
Immunovant Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Immunovant is extremely important. It helps to project a fair market value of Immunovant Stock properly, considering its historical fundamentals such as Net Income. Since Immunovant's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunovant's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunovant's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Immunovant introduce new products? Factors like these will boost the valuation of Immunovant. Market participants price Immunovant higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Immunovant listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Understanding Immunovant requires distinguishing between market price and book value, where the latter reflects Immunovant's accounting equity. The concept of intrinsic value - what Immunovant's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Immunovant's price substantially above or below its fundamental value.
Please note, there is a significant difference between Immunovant's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunovant is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Immunovant's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Immunovant 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Immunovant's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Immunovant.
| 11/20/2025 |
| 02/18/2026 |
If you would invest 0.00 in Immunovant on November 20, 2025 and sell it all today you would earn a total of 0.00 from holding Immunovant or generate 0.0% return on investment in Immunovant over 90 days. Immunovant is related to or competes with Crinetics Pharmaceuticals, Viking Therapeutics, Kymera Therapeutics, NewAmsterdam Pharma, Praxis Precision, Dyne Therapeutics, and ACADIA Pharmaceuticals. Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoim... More
Immunovant Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Immunovant's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Immunovant upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.54 | |||
| Information Ratio | 0.0667 | |||
| Maximum Drawdown | 15.37 | |||
| Value At Risk | (3.63) | |||
| Potential Upside | 4.47 |
Immunovant Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunovant's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Immunovant's standard deviation. In reality, there are many statistical measures that can use Immunovant historical prices to predict the future Immunovant's volatility.| Risk Adjusted Performance | 0.0745 | |||
| Jensen Alpha | 0.186 | |||
| Total Risk Alpha | 0.0807 | |||
| Sortino Ratio | 0.0787 | |||
| Treynor Ratio | 0.1842 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Immunovant's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Immunovant February 18, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0745 | |||
| Market Risk Adjusted Performance | 0.1942 | |||
| Mean Deviation | 2.32 | |||
| Semi Deviation | 2.45 | |||
| Downside Deviation | 2.54 | |||
| Coefficient Of Variation | 1184.46 | |||
| Standard Deviation | 2.99 | |||
| Variance | 8.96 | |||
| Information Ratio | 0.0667 | |||
| Jensen Alpha | 0.186 | |||
| Total Risk Alpha | 0.0807 | |||
| Sortino Ratio | 0.0787 | |||
| Treynor Ratio | 0.1842 | |||
| Maximum Drawdown | 15.37 | |||
| Value At Risk | (3.63) | |||
| Potential Upside | 4.47 | |||
| Downside Variance | 6.44 | |||
| Semi Variance | 5.98 | |||
| Expected Short fall | (2.57) | |||
| Skewness | 0.9954 | |||
| Kurtosis | 2.98 |
Immunovant Backtested Returns
Immunovant appears to be very steady, given 3 months investment horizon. Immunovant holds Efficiency (Sharpe) Ratio of 0.0943, which attests that the entity had a 0.0943 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Immunovant, which you can use to evaluate the volatility of the firm. Please utilize Immunovant's Market Risk Adjusted Performance of 0.1942, risk adjusted performance of 0.0745, and Downside Deviation of 2.54 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Immunovant holds a performance score of 7. The company retains a Market Volatility (i.e., Beta) of 1.32, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immunovant will likely underperform. Please check Immunovant's maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Immunovant's current trending patterns will revert.
Auto-correlation | -0.12 |
Insignificant reverse predictability
Immunovant has insignificant reverse predictability. Overlapping area represents the amount of predictability between Immunovant time series from 20th of November 2025 to 4th of January 2026 and 4th of January 2026 to 18th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Immunovant price movement. The serial correlation of -0.12 indicates that less than 12.0% of current Immunovant price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.12 | |
| Spearman Rank Test | -0.01 | |
| Residual Average | 0.0 | |
| Price Variance | 0.44 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Immunovant Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Immunovant reported net income of (413.84 Million). This is 221.26% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 172.48% higher than that of the company.
Immunovant Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunovant's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunovant could also be used in its relative valuation, which is a method of valuing Immunovant by comparing valuation metrics of similar companies.Immunovant is currently under evaluation in net income category among its peers.
Immunovant ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Immunovant's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Immunovant's managers, analysts, and investors.Environmental | Governance | Social |
Immunovant Institutional Holders
Institutional Holdings refers to the ownership stake in Immunovant that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Immunovant's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immunovant's value.| Shares | Two Seas Capital Lp | 2025-06-30 | 2.3 M | Perceptive Advisors Llc | 2025-06-30 | 2.1 M | Geode Capital Management, Llc | 2025-06-30 | 1.8 M | Woodline Partners Lp | 2025-06-30 | 1.5 M | Stempoint Capital Lp | 2025-06-30 | 1.3 M | Goldman Sachs Group Inc | 2025-06-30 | 1.2 M | Pictet Asset Manangement Sa | 2025-06-30 | 1.2 M | Aberdeen Group Plc | 2025-06-30 | 844.7 K | Norges Bank | 2025-06-30 | 687.7 K | Fmr Inc | 2025-06-30 | 18.6 M | Deep Track Capital, Lp | 2025-06-30 | 9.5 M |
Immunovant Fundamentals
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 4.53 B | ||||
| Shares Outstanding | 203.53 M | ||||
| Shares Owned By Insiders | 57.04 % | ||||
| Shares Owned By Institutions | 51.14 % | ||||
| Number Of Shares Shorted | 16.49 M | ||||
| Price To Book | 5.31 X | ||||
| EBITDA | (437.77 M) | ||||
| Net Income | (413.84 M) | ||||
| Cash And Equivalents | 427.2 M | ||||
| Cash Per Share | 3.66 X | ||||
| Total Debt | 98 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 21.48 X | ||||
| Book Value Per Share | 4.85 X | ||||
| Cash Flow From Operations | (375.87 M) | ||||
| Short Ratio | 11.10 X | ||||
| Earnings Per Share | (2.67) X | ||||
| Target Price | 40.63 | ||||
| Number Of Employees | 362 | ||||
| Beta | 0.62 | ||||
| Market Capitalization | 5.24 B | ||||
| Total Asset | 776.22 M | ||||
| Retained Earnings | (1.24 B) | ||||
| Working Capital | 698.89 M | ||||
| Net Asset | 776.22 M |
About Immunovant Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunovant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunovant using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunovant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.